MOTS-c is a mitochondria-derived peptide that regulates metabolic homeostasis, and the community runs it mainly for exercise performance and body composition, with a second group targeting metabolic health and insulin sensitivity; both draw largely positive reports. People commonly take around 5 mg a day, spanning 60 mcg to 50 mg, and the clinician protocols that exist agree on 5 mg daily subcutaneous, sometimes over four-to-six-week cycles. A handful of reports mention sleep changes, an injection-site reaction, or mild GI, but none of these is a consistent theme. The caveat to carry: there's no FDA-approved indication, and the off-label evidence base is thinner than the discourse suggests.
Data last updated
Measured on 5 of 6 axes
Evidence shape
Human evidence for MOTS-c is limited — pilot studies, withdrawn trials, or completed trials without posted results. Off-label / exploratory data exists for 2 additional indications (Prediabetes; Diagnostic & mechanistic studies).
Efficacy signal
Completed studies are present, but primary-endpoint pass/fail classification is not yet clean enough to score. These are the currently projected indication-level signals.
Prediabetes
1 study
Diagnostic & mechanistic studies
1 study
No completed study rows are available for endpoint scoring yet.
Human evidence
Lower-tier support
Published literature
Standalone PubMed / Europe PMC publications matched to this peptide and deduped by identifier. Trial records and animal / in-vitro rows are surfaced above; these are the human-relevant papers behind them.
Source data
Clinical research side effects
Clinical safety table not projected yet.
Anecdotal side effects
price offers can be sorted by column
How MOTS-C is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.
No structured protocol details captured for this tier yet.
This tier has no reliably captured dosing information; zero completed trials were identified, so no amount, frequency, or cycling can be stated.
Two sources agree on a 5 mg subcutaneous injection taken daily, with no cycling protocol specified, and the dosing pattern is consistent across the available clinician reports.
Most users report taking around 2 mg of MOTS‑C on an unstated schedule, while a notable minority dose weekly (≈5 mg) or daily (≈1 mg); the majority use it continuously, with only a few following a 5‑days‑on/2‑days‑off cycle.